Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
Member, St. Jude Faculty
Chair, Pharmaceutical Sciences
Pharmaceutical Sciences
Mary Relling, PharmD
Pharmaceutical Sciences
MS313, Room I5112
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: mary.relling@stjude.org
Phone: (901) 595-2348
FAX: (901) 525-8869
BS - University of Arizona
PharmD - University of Utah College of Pharmacy
Improving the drug therapy of childhood leukemia
Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, Stoddard A, Yang W, Smith C,Fernandez CA, Cross SJ, Haidar C, Baker DK, Howard SC, Evans WE, Broeckel U, Relling MV. A clinician driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharm Ther 2012 (in press).
Kawedia JD, Liu C, Pei D, Cheng C, Fernandez CA, Howard SC, Campana D, Panetta JC, Bowman WP, Evans WE, Pui CH, Relling MV. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 119:1658-64, 2012. (PMCID: PMC3286344)
Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE; Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 89:387-91, 2011. (PMCID: PMC3098761)
Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE; Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 89:387-91, 2011. (PMCID: PMC3098761)
Relling MV, Klein TE. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 89:464-7, 2011. (PMCID: PMC3098762)
Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D, Yang W, Neale G, Cox NJ, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Willman CL, Bowman WP, Camitta BM, Carroll A, Reaman GH, Carroll WL, Loh M, Hunger SP, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 43:237-41, 2011. (PMCID: PMC3104508)
Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, Neale G, Howard SC, Evans WE, Pui CH, Relling MV. Pharmacokinetic, pharmacodynamic and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood December 10, 2010.
Relling MV, Altman RB, Goetz MP, Evans WE. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol April 20, 2010.
Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV. Treatment of childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med Jun 25;360(26):2730-41, 2009.
Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009.
Yang L, Boyd K, Kaste SC, Kamdem LK, Rahija RJ, Relling MV. A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. J Orthop Res 27:169-175, 2008.
Yang J, Cheng C, Yang W, Pei D, Cao X, Fan Y, Pounds S, Trevino L, French D, Campana D, Downing J, Evans WE, Pui C, Devidas M, Bowman W, Camitta B, Willman CL, Davies S, Borowitz M, Carroll WL, Hunger SP, Relling MV. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301:393-403, 2009.
Yang J, Bhojwani D, Yang W, Cai X, Stocco G, Crews K, Wang J, Morrison D, Devidas M, Hunger SP, Willman CL, Raetz EA, Pui C, Evans WE, Relling MV, Carroll WL. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 112:4178-83, 2008.
Davies SM, Borowitz MJ, Rosner GL, Ritz K, Devidas M, Winick N, Martin PL, Bowman P, Elliott J, Willman C, Das S, Cook EH, Relling MV. Pharmacogenetics of minimal residual disease response in children with Acute Lymphoblastic Leukemia (ALL): a report from the Children's Oncology Group. Blood 111:2984-90, 2008.
Hartford C, Vasquez E, Schwab M, Edick MJ, Rehg JE, Grosveld G, Pui CH, Evans WE, Relling MV. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res 67: 4965-72, 2007.
Jones TS, Yang W, Evans WE, Relling MV. Using HapMap tools in pharmacogenomic discovery: The thiopurine methyltransferase polymorphism. Clin Pharmacol Ther 81:729-34, 2007.
Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-64, 2007.
Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, Hijiya N, Rizzari C, Rosner GL, Frudakis T, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109:4151-7, 2007.
Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Schuldiner AR, Weinshilboum RM, Weiss ST. Pharmacogenomics: challenges and opportunities. Ann Intern Med 145:749-57, 2006.
French D, Wilkinson MR, Yang W, de chaisemartin L, Cook EH, Das S, Ratain MJ, Evans WE, Downing JR, Pui CH, Relling MV. Global gene expression as a function of germline genetic variation. Hum Mol Genet 14:1621-1629, 2005.
Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, Sandlund JT, Rubnitz J, Ribeiro R, Pui CH, Evans WE, Relling MV. Pharmacogenetics of Outcome in Children with Acute Lymphoblastic Leukemia. Blood 105: 4752-4758, 2005.
Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M, Howard S, Ribeiro R, Sandlund JT, Pui Ch, Kaste SC. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 22:3930-3936, 2004.
Holleman A, Cheok MH, den Boer ML, Yang W, Veerman A, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R, Evans WE. Gene Expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351:533-542, 2004.
Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468, 2004.
Pui CH, Relling MV, Downing JR. Acute Lymphoblastic leukemia. N Engl J Med 350:1535-1548, 2004.
Blanco JG, Edick MJ, Relling MV. Etoposide induces chimeric Mll gene fusions. FASEB J 18:173-175, 2004.
Relling MV, Boyett JM, Blanco JG, Raimondi S, Behm FG, Sandlund JT, Rivera GK, Kun LE, Evans WE, Pui C-H. Granulocyte-colony stimulating factor and the risk of secondary myeloid malignancy after etoposide. Blood 101:3862-3867, 2003.
Blanco JG, Dervieux T, Edick M, Mehta PK, Rubnitz JE, Shurtleff S, Raimondi SC, Behm FG, Pui CH, Relling MV. Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci USA 98:10338-10343, 2001.
Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nature Rev Cancer 1:99-108, 2001.
Ratain MJ, Relling MV. Gazing into a crystal ball - cancer therapy in the post-genomic era. Nat Med 7:285-287, 2001.
Relling MV, Pui C-H, Sandlund JT, Rivera GK, Hancock ML, Boyett JB, Evans WE. Chronic anticonvulsant therapy reduces the efficacy of chemotherapy for childhood acute lymphoblastic leukemia. Lancet 356:285-290, 2000.
Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001-2008, 1999.
Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491, 1999.
Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE, Walter AW, Evans WE, Pui C-H. High incidence of secondary brain tumors related to irradiation and antimetabolite therapy. Lancet 354:34-39, 1999.
Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui C-H. Conventional versus individualized doses of chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998.
Last update: July 2012
Prescribing Gets Personal